D. E. Shaw & Co., Inc. Sutro Biopharma, Inc. Transaction History

D. E. Shaw & Co., Inc.

$114 Billion
Q1 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Sutro Biopharma, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 241,643 shares of STRO stock, worth $695,931. This represents 0.0% of its overall portfolio holdings.

Number of Shares

241,643

Holding current value

$695,931

% of portfolio

0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$3.27 - $5.65 $790,172 - $1.37 Million	241,643 New	241,643 $1.37 Million
Q2 2023 Aug 14, 2023	SELL	$4.25 - $5.88 $486,523 - $673,118	-114,476 Reduced 73.76%	40,723 $189,000
Q1 2023 May 15, 2023	SELL	$4.48 - $8.45 $539,356 - $1.02 Million	-120,392 Reduced 43.69%	155,199 $717,000
Q4 2022 Feb 14, 2023	SELL	$5.41 - $8.08 $213,278 - $318,537	-39,423 Reduced 12.51%	275,591 $2.23 Million
Q3 2022 Nov 14, 2022	BUY	$5.17 - $7.11 $287,539 - $395,436	55,617 Added 21.44%	315,014 $1.75 Million

Q2 2022 Aug 15, 2022	BUY	$3.41 - $8.95 $884,543 - $2.32 Million	259,397 New	259,397 $1.35 Million
Q1 2022 May 16, 2022	SELL	$7.78 - $15.31 $238,565 - $469,465	-30,664 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$14.25 - $23.53 $95,802 - $158,192	-6,723 Reduced 17.98%	30,664 $456,000
Q3 2021 Nov 15, 2021	BUY	$16.88 - $22.38 $141,960 - $188,215	8,410 Added 29.02%	37,387 $706,000
Q2 2021 Aug 16, 2021	SELL	$18.03 - $23.82 $245,730 - $324,642	-13,629 Reduced 31.99%	28,977 $539,000
Q1 2021 May 17, 2021	SELL	$20.29 - $27.54 $1.14 Million - $1.54 Million	-56,025 Reduced 56.8%	42,606 $970,000
Q4 2020 Feb 16, 2021	BUY	$10.16 - $23.98 $1 Million - $2.37 Million	98,631 New	98,631 $2.14 Million

Others Institutions Holding STRO

# of Institutions

122

Shares Held

53.3M

Call Options Held

7.8K

Put Options Held

2.4K

View Full List

About SUTRO BIOPHARMA, INC.

Ticker STRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,161,500
Market Cap $150M
Description
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-dr...

More about STRO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account